Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
ConditionHematologic Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age65+
SponsorRonald Paquette
About this trial
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Eligibility criteria
Qualifiers
Patient age >/= 65 years
Patient and related Donor (if applicable) sign the Informed Consent Form for the study. If donor is unrelated, donor does not sign Informed Consent Form and this will not affect recipient study eligibility.
Patient meets standard criteria for allogeneic stem cell transplant
Patient is deemed suitable to receive Flu/TBI 800 conditioning regimen as standard of care transplant
Disqualifiers
Patient has a diagnosis of myelofibrosis
Patient has high titer antibodies (>10,000 mean fluorescent intensity) against one or more donor HLA antigens
Patient has undergone prior autologous or allogeneic stem cell transplant
Requiring sedation for cardiac MRIs.
Trial design
Treatments tested in this trial
- Cyclophosphamide
Treatment groups
26 Participants
are divided into 1 treatment groupSponsors and collaborators
Ronald Paquette
Lead sponsor
Cedars-Sinai Medical Center
Sponsor institution
Source ClinicalTrials.gov